Luciano Messina

Luciano Messina

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in FEMS Yeast Research
Verified
Journal Article
Open access
PDF file
CBCarmelo Biondo
Carmelo Biondo
GMGiuseppe Mancuso
Giuseppe Mancuso
AMAngelina Midiri
Angelina Midiri
Mauro BombaciMauro Bombaci
Mauro Bombaci
LMLuciano Messina
Luciano Messina
GTGiuseppe Teti
Giuseppe Teti
The characterization of proteins secreted by Cryptococcus neoformans is of relevance to the identification of vaccine candidates, because concentrate

17 June 2016 in FEBS Letters
Verified
Journal Article
Open access
PDF file
LMLuciano Messina
Luciano Messina
Jose A. GaviraJose A. Gavira
Jose A. Gavira
Salvatore PernagalloSalvatore Pernagallo
Salvatore Pernagallo
JUJuan D. Unciti‐Broceta
Juan D. Unciti‐Broceta
RSRosario María Sánchez-Martín
Rosario María Sánchez-Martín
CSCynthia Secchieri
Cynthia Secchieri
Hyaluronidases (Hyals) are broadly used in medical applications to facilitate the dispersion and/or absorption of fluids or medications. This study reports the isolation, cloning, and industrial‐scale recombinant production, purification and full characterization, including X‐ray structure determination at 1.45 Å, of an extracellular Hyal from the nonpathogenic bacterium Streptomyces koganeiensis. The recombinant S. koganeiensis Hyal (rHyal_Sk) has a novel bacterial catalytic domain with high enzymatic activity, compared with commercially available Hyals, and is more thermostable and presents higher proteolytic resistance, with activity over a broad pH range. Moreover, rHyal_Sk exhibits remarkable substrate specificity for hyaluronic acid (HA) and poses no risk of animal cross‐infection.

31 May 2019 in International Wound Journal
Verified
Journal Article
Closed access
PDF file
RPRoberta Di Pasquale
Roberta Di Pasquale
SVSusanna Vaccaro
Susanna Vaccaro
MCMichele Caputo
Michele Caputo
CCChristian Cuppari
Christian Cuppari
SCSalvatore Caruso
Salvatore Caruso
LMLuciano Messina
Luciano Messina

28 October 2018 in Cancers
Verified
Journal Article
Open access
PDF file
MRMariangela De Robertis
Mariangela De Robertis
LPLise Pasquet
Lise Pasquet
LLLuisa Loiacono
Luisa Loiacono
EBElisabeth Bellard
Elisabeth Bellard
LMLuciano Messina
Luciano Messina
ESEmanuela Signori
Emanuela Signori
Cancer vaccines based on plasmid DNA represent a good therapeutic perspective, despite their low potency. Animal-derived hyaluronidases (Hyals) are employed in oncological clinical practice. Hyal has been also demonstrated to be a good enhancer of intramuscular Gene Electro-Transfer (GET) efficiency in anti-cancer preclinical protocols, with increased transfected cells and higher expression of the encoded genes. Nevertheless, the use of animal-derived Hyals results limited respect to their potentialities, since such preparations could be affected by low purity, variable potency and uncertain safety. To improve the delivery of intramuscular GET-based protocols in mouse, we investigated a new recombinant Hyal, the rHyal-sk, to assess in vivo safety and activity of this treatment at cellular and biochemical levels. We evaluated the cellular events and the inflammation chemical mediators involved at different time points after rHyal-sk administration plus GET. Our results demonstrated the in vivo safety and efficacy of rHyal-sk when injected once intramuscularly in association with GET, with no toxicity, good plasmid in-take ability, useful inflammatory response activation, and low immunogenicity. Following these findings, we would recommend the use of the new rHyal-sk for the delivery of DNA-based vaccines and immunotherapy, as well as into clinical practice, for tumor disease treatments.

15 February 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
RSRosalba Siracusa
Rosalba Siracusa
Daniela ImpellizzeriDaniela Impellizzeri
Daniela Impellizzeri
Marika CordaroMarika Cordaro
Marika Cordaro
APAlessio Filippo Peritore
Alessio Filippo Peritore
ENRICO GUGLIANDOLOENRICO GUGLIANDOLO
ENRICO GUGLIANDOLO
RPRosanna Di paola
Rosanna Di paola
Osteoarthritis (OA) is a disease that currently has no cure. There are numerous studies showing that carnosine and hyaluronic acid (HA) have a positive pharmacological action during joint inflammation. For this reason, the goal of this research was to discover the protective effect of a new carnosine conjugate with hyaluronic acid (FidHycarn) on the inflammatory response and on the cartilage degradation in an in vivo experimental model of OA. This model was induced by a single intra-articular (i.ar.) injection of 25 µL of normal saline with 1 mg of monosodium iodoacetate solution (MIA) in the knee joint of rats. MIA injection caused histological alterations and degradation of the cartilage, as well as behavioral changes. Oral treatment with FidHycarn ameliorated the macroscopic signs, improved thermal hyperalgesia and the weight distribution of the hind paw, and decreased histological and radiographic alterations. The oxidative damage was analyzed by evaluating the levels of nitrotyrosine and inducible nitric oxide synthase (iNOS) that were significantly reduced in FidHycarn rats. Moreover, the levels of pro-inflammatory cytokines and chemokines were also significantly reduced by FidHycarn. Therefore, for the first time, the effectiveness of oral administration of FidHycarn has been demonstrated in an osteoarthritis model. In conclusion, the new FidHycarn could represent an interesting therapeutic strategy to combat osteoarthritis.

30 March 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
VLValeria Lanza
Valeria Lanza
VGValentina Greco
Valentina Greco
EBEleonora Bocchieri
Eleonora Bocchieri
SSSebastiano Sciuto
Sebastiano Sciuto
RIRosanna Inturri
Rosanna Inturri
Enrico RizzarelliEnrico Rizzarelli
Enrico Rizzarelli
Hyaluronic acid (Hy) is a natural linear polymer that is widely distributed in different organisms, especially in the articular cartilage and the synovial fluid. During tissue injury due to oxidative stress, Hy plays an important protective role. All the beneficial properties of Hy make the polymer attractive for many biomedical uses; however, the low stability and short biological half-life limit Hy application. To overcome these problems, the addition of small antioxidant molecules to Hy solution has been employed to protect the molecular integrity of Hy or delay its degradation. Carnosine (β-alanyl-L-histidine, Car) protects cells from the damage due to the reactive species derived from oxygen (ROS), nitrogen (RNS) or carbonyl groups (RCS). Car inhibits the degradation of hyaluronan induced by free radical processes in vitro but, like Hy, the potential protective action of Car is drastically hampered by the enzymatic hydrolysis in vivo. Recently, we conjugated Hy to Car and the derivatives (HyCar) showed protective effects in experimental models of osteoarthritis and rheumatoid arthritis in vivo. Here we report the antioxidant activity exerted by HyCar against ROS, RNS and RCS. Moreover, we tested if the covalent conjugation between Hy and Car inhibits the enzymatic hydrolysis of the polymer and the dipeptide backbone. We found that the antioxidant properties and the resistance to the enzymatic hydrolysis of Hy and Car are greatly improved by the conjugation.